The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.124.7.900

Three categories of background factors were found to predict short-term improvement (symptom reduction) in schizophrenic patients receiving either placebo or one of three phenothiazines: general predictors, which applied equally to all treatments; predictors of outcome under placebo but not under drug treatment, or vice versa; and predictors of outcome under one phenothiazine but not another. Some variables found by other investigators to predict outcome were not found to be predictors in this study; it is suggested that these variables are not related to the specific outcome measure of symptom reduction.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.